

S2 Table. Supportive and anti-viral medications in the early remdesivir and late remdesivir-cohort

	No remdesivir (n=107)	Early remdesivir (n=107)	Late remdesivir (n=109)	<i>P-value</i>
COVID-19 severity status [®]	51 (48)	17 (16)	24 (22)	0.001
Supportive medications [#]				
Tocilizumab	55 (51)	36 (34)	42 (38)	0.024
Antiviral medications [*]				
Favipiravir	20 (19)	8 (8)	14 (13)	0.051
Interferon beta-1b	19 (18)	10 (10)	10 (11)	0.088
Interferon beta-1b and favipiravir	19 (18)	7 (7)	16 (15)	0.042
Interferon beta-1b, lopinavir-ritonavir, and ribavirin	13 (12)	5 (5)	10 (9)	0.147
Lopinavir-ritonavir	12 (11)	4 (4)	8 (7)	0.114

Data are n (%). [®] COVID-19 severity status is defined as a COVID-19 pneumonia requiring high-flow oxygen therapy or non-invasive ventilation. [#]All the patients received systemic corticosteroids including dexamethasone 6 mg daily, or methylprednisolone with 2 mg/kg/day starting dose and max 60 mg/day for pulse dosing. ^{*}Antiviral therapies before the initiation of remdesivir. Abbreviation: COVID-19, coronavirus disease 2019.